{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:51:32Z","timestamp":1791107492777,"version":"4.1.0"},"reference-count":61,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,6,28]],"date-time":"2005-06-28T00:00:00Z","timestamp":1119916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> In the last years, marked progress has been made in the treatment of chronic hepatitis B. The efficacy of lamivudine, the first nucleoside analogue available, is limited by the high incidence of resistance. Adefovir, which was recently approved has a comparable efficacy with a very low frequency of resistance. However, adefovir needs to be indefinitely administered as withdrawal of therapy is generally associated with reactivation and sustained response is uncommon.<\/jats:p><jats:p>Recent large randomized controlled trials showed that PEG IFNs induce relatively high sustained response rates both in HBeAg positive and HBeAg negative chronic hepatitis B. So far, the combination of PEG IFN with lamivudine, used simultaneously, is disappointing in terms of short\u2010term efficacy. However, long\u2010term efficacy needs to be assessed and different schedules of combination (for example sequential) need to be evaluated.<\/jats:p><jats:p>A number of nucleoside analogues, with favourable toxicity profiles and a promise of increased effectiveness against HBV, are at various stages of clinical development. Results of phase III trials of entecavir and emtricitabine confirmed their efficacy. However, while entecavir is associated with a low incidences of resistance, emtricitabine is associated with a relatively high incidence of resistance which limits its use as a monotherapy. The efficacy and safety of new and more potent drugs like telbivudine and clevudine need to be confirmed.<\/jats:p><jats:p>The future of chronic hepatitis B therapy seems to be in the combination of different drugs. Ideally, the optimal drugs to combine would meet the following criteria: they should have different sites of action on HBV DNA replication, a potent antiviral effect, an excellent safety profile and they should induce a sustained response with a limited duration of therapy. Indeed, the concept of combination therapy has been recently developed in order to increase efficacy and to decrease the occurrence of viral resistance. However, so far few combinations have been evaluated. No combination therapy demonstrated a benefit as compared with monotherapy. More potent drugs and new combinations together with the understanding of the mechanisms of resistance to therapy are important challenges to improve the efficacy of treatment and decrease in the future the global burden related to chronic hepatitis B.<\/jats:p>","DOI":"10.1111\/j.1365-2893.2005.00599.x","type":"journal-article","created":{"date-parts":[[2005,6,30]],"date-time":"2005-06-30T12:57:27Z","timestamp":1120136247000},"page":"333-345","source":"Crossref","is-referenced-by-count":65,"title":["Treatment of chronic hepatitis B"],"prefix":"10.1111","volume":"12","author":[{"given":"P.","family":"Marcellin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,6,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00431-2"},{"issue":"1","key":"e_1_2_8_3_2","first-page":"S3","article-title":"Consensus Statement (long version)","volume":"39","author":"EASL International Consensus Conference on Hepatitis B","year":"2003","journal-title":"J Hepatol"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.24839"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701303360507"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00011"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000024968"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00319-2"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00207-1"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(91)91712-P"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807093390201"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411702"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.4.562"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00076-X"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34294"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.16333"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25084"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.8559"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80191-8"},{"key":"e_1_2_8_20_2","author":"Martinot M","year":"2003","journal-title":"Evaluation of TrugeneTM HBV Genotyping Kit (Research Use Only), Sequence Based Genotyping Assay for Determination of Mutations and Viral Genotype. Viral Hepatitis and Liver Disease"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290321"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33894"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.17912"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21554"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310130"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-9-199611010-00001"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300525"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020681"},{"key":"e_1_2_8_29_2","first-page":"1869","article-title":"Adefovir dipivoxil (ADV) 10\u2003mg: results in consistent histological improvement in HBeAg+ and HBeAg\u2212 patients regardless of baseline demographic or disease characteristics","volume":"4","author":"Marcellin P","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_8_30_2","first-page":"373A","article-title":"Adefovir dipivoxil (ADV) 10\u2003mg for the treatment of patients with HbeAg+ chronic hepatitis B: continued efficacy beyond 48\u2003weeks","volume":"36","author":"Marcellin P","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34740"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021812"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(04)90046-3"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.050"},{"key":"e_1_2_8_35_2","first-page":"446A","article-title":"Safety and efficacy of adefovir dipivoxil for the treatment of lamivudine resistant HBV in patients post liver transplantation","volume":"34","author":"Schiff ER","year":"2001","journal-title":"Hepatology"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05840-8"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26371"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012073432301"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00450.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00352-0"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0"},{"issue":"4","key":"e_1_2_8_42_2","first-page":"20A","article-title":"Peginterferon Alfa\u20102a (40KD) (Pegasys) Monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HbeAg\u2010positive chronic hepatitis B","volume":"40","author":"Lau G","year":"2004","journal-title":"Hepatology"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040431"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.051"},{"issue":"2","key":"e_1_2_8_45_2","first-page":"69","article-title":"A randomised double\u2010blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment na\u00efve patients with chronic hepatitis B (CHB): week 52 analysis","volume":"38","author":"Sung JJY","year":"2003","journal-title":"J Hepatol"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904223401608"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26815"},{"key":"e_1_2_8_48_2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1128\/AAC.43.1.190","article-title":"Metabolic studies on BMS\u2010200475, a new antiviral compound active against hepatitis B virus","volume":"43","author":"Yamanaka G","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37058"},{"key":"e_1_2_8_50_2","first-page":"340A","article-title":"Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy","volume":"34","author":"Tassopoulos N","year":"2001","journal-title":"Hepatology"},{"issue":"4","key":"e_1_2_8_51_2","first-page":"70A","article-title":"Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: Results of phase III study ETV\u2010022 in nucleoside\u2010naive patients","volume":"40","author":"Chang TT","year":"2004","journal-title":"Hepatology"},{"issue":"4","key":"e_1_2_8_52_2","first-page":"1140A","article-title":"Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients","volume":"40","author":"Colonno RJ","year":"2004","journal-title":"Hepatology"},{"key":"e_1_2_8_53_2","first-page":"349A","article-title":"A randomized, double\u2010blind comparison of 3 doses of emtricitabine in patients with chronic hepatitis B given 48\u2003weeks of treatment","volume":"34","author":"Leung N","year":"2001","journal-title":"Hepatology"},{"key":"e_1_2_8_54_2","first-page":"323A","article-title":"Antiviral activity of 48\u2003weeks of emtricitabine treatment in patients with HBeAg negative\/HBV DNA positive chronic Hepatitis B","volume":"34","author":"Wang C","year":"2001","journal-title":"Hepatology"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(00)00069-3"},{"key":"e_1_2_8_56_2","first-page":"321A","article-title":"Safe and potent suppression of Hepatitis B virus with l\u2010deoxythymidine: results of a dose\u2010escalation trial","volume":"34","author":"Lai CL","year":"2001","journal-title":"Hepatology"},{"key":"e_1_2_8_57_2","first-page":"629A","article-title":"Phase 1 dose\u2010escalation pharmacokinetics of l\u2010deoxithymidine in patients with chronic hepatitis B virus infection","volume":"34","author":"Zhou XJ","year":"2001","journal-title":"Hepatology"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(04)90042-6"},{"key":"e_1_2_8_59_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.42.2.369","article-title":"Inhibitory effect of 2\u2032fluoro\u20105\u2010methyl\u2010beta\u2010l\u2010arabinofuranosyl uracil on duck hepatitis B virus replication","volume":"42","author":"Aguesse\u2010Germon S","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.20899"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20257"},{"key":"e_1_2_8_62_2","first-page":"1129","article-title":"A phase II randomized trial evaluating the safety, pharmacokinetics and anti\u2010viral activity of clevudine for 12 weeks in chronic hepatitis B","author":"Marcellin P","year":"2004","journal-title":"Hepatology"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2005.00599.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2005.00599.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T15:12:35Z","timestamp":1697296355000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2005.00599.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,28]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1365-2893.2005.00599.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2005.00599.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,28]]}}}